| Hazard Information | Back Directory | [Uses]
PF-03049423 (Compound PF-5) is a potent and highly selective phosphodiesterase-5A inhibitor with an IC50 of about 0.2 nM for rat and human platelet enzyme. PF-03049423 can be used for the research of acute ischaemic stroke[1]. | [in vivo]
PF-03049423 (Compound PF-5) (1-10 mg/kg; s.c.; b.i.d. for 7 days) promotes functional recovery in a rat model of severe stroke induced by permanent middle cerebral artery occlusion[1].
PF-03049423 (1.0 mg/kg b.i.d. or 0.6 mg/kg q.d. for 7 days) improves poststroke sensory–motor behavioral outcome even when the treatment is initiated 24-72 hours after occlusion[1]. | Animal Model: | Male Sprague-Dawley rats, middle cerebral artery occlusion (MCA-o) model[1] | | Dosage: | 0.1, 1, or 10 mg/kg | | Administration: | Subcutaneous injection, b.i.d. for 7 days | | Result: | Improved functional recovery at 1 mg/kg and 10 mg/kg. |
| [IC 50]
PDE5A; rat and human platelet enzyme: ~0.2 nM (IC50) | [References]
[1] Menniti FS, et al. Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism. J Pharmacol Exp Ther. 2009 Dec;331(3):842-50. DOI:10.1124/jpet.109.156919 |
|
|